Spike train replicability of CA1 pyramidal cell model with event-based input encoding. by Evan Cudone (5768813)

Average self-reported physical health ratings before or during the COVID-19 pandemic among individuals who engaged during the pandemic in more than 3 (A), 4 (B), or 5 (C) positive... by Elie Mulhem (22537863)

Subjects:

DataSheet_1_Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma.docx by Simon Le Gallou (10742601)

“…<p>Absolute count of circulating monocytes has been proposed as an independent prognostic factor in diffuse large B-cell lymphoma (DLBCL). However, monocyte nomenclature includes various subsets with pro-, anti-inflammatory, or suppressive functions, and their clinical relevance in DLBCL has been poorly explored. …”

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Decreased presence of tubulin-GFP at axonal MTs in a pulse chase experiment suggests changes in MT replenishment with age. by Pilar Okenve-Ramos (18150546)

IpaH9.8 mutants display decreased activity to degrade the GBPs. by Chenggong Ji (6858425)

Deletion of murine <i>Rhoh</i> leads to de-repression of <i>Bcl-6</i> via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma by Hiroto Horiguchi (3215001)

“…RHOH was initially identified as a translocation partner with BCL-6 in non-Hodgkin lymphoma (NHL), and aberrant somatic hypermutation (SHM) in the 5ʹ untranslated region of the RHOH gene has also been detected in Diffuse Large B-Cell Lymphoma (DLBCL). Recent data suggest a correlation between RhoH expression and disease progression in Acute Myeloid Leukaemia (AML). …”

Fig 1 - by Gláucia Helena Fernandes Seixas (5866511)

DataSheet_1_Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.xlsx by Boram Lee (549836)

“…The genes most frequently altered (> 20%) were (in decreasing order of frequency) CDKN2A, PIM1, CD79B, TP53, MYD88, MYC, BTG2, BTG1, CDKN2B, DTX1, CD58, ETV6, and IRF4. …”

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. by Peiqi Yin (6533747)

Effects of nuclear hormone treatments on <i>kcnk5b</i>, <i>rcan2</i>, and control genes in pectoral fin buds and adult fins and sufficiency/necessity experiments for <i>rcan2</i>. by Xiaowen Jiang (8291814)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Foldases and holdases each decrease the level of unfolded protein. by Adam MR de Graff (9767829)

Silkworm ovaries and ovarioles infected by <i>N</i>. <i>bombycis</i>. by Chunxia Wang (766713)

Subjects:

The infection of follicle and nurse cells by <i>N</i>. <i>bombycis</i>. by Chunxia Wang (766713)

Subjects:

Decreased UFA/SFA ratio induces cytosolic chaperones. by Dongyeop Lee (108880)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects: